Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan

Published:2021-03 Issue:3 Volume:27 Page:241.e1-241.e11
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Wakase Shiho,Teshima Takanori,Zhang Jie,Ma Qiufei,Watanabe Yoko,Yang Hongbo,Qi Cynthia Z.,Chai Xinglei,Xie Yanwen,Wu Eric Q.,Igarashi Ataru

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference64 articles.

1. Acute lymphoblastic leukemia in children;Hunger;N Engl J Med,2015

2. Acute lymphoblastic leukaemia;Inaba;Lancet,2013

3. Surveillance Epidemiology and End Results Program. Cancer stat facts: leukemia—acute lymphocytic leukemia (ALL). Available at: https://seer.cancer.gov/statfacts/html/alyl.html. Accessed June 15, 2020.

4. Childhood and adolescent cancer statistics, 2014;Ward;CA Cancer J Clin,2014

5. The Japan Society for Hematopoietic Cell Transplantation. Hematopoietic cell transplantation guidelines-pediatric acute lymphoblastic leukemia, third edition. Available at: https://www.jshct.com/uploads/files/guideline/03_04_all_ped03.pdf. Accessed May 15, 2020.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

3. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study;Applied Health Economics and Health Policy;2024-04-29

4. Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis;Cancer Reports;2024-01-13

5. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma;Transplantation and Cellular Therapy;2024-01